About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 698327, 9 pages
http://dx.doi.org/10.1155/2012/698327
Review Article

Recent Understanding on Diagnosis and Management of Central Nervous System Vasculitis in Children

1Department of Ophthalmology, Ocular Immunovirology Service, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy
2Department of Pediatrics, Child Neurology Division, Sapienza University of Rome, 00185 Rome, Italy

Received 30 March 2012; Revised 28 May 2012; Accepted 13 August 2012

Academic Editor: Rolando Cimaz

Copyright © 2012 Ludovico Iannetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Benseler and R. Schneider, “Central nervous system vasculitis in children,” Current Opinion in Rheumatology, vol. 16, no. 1, pp. 43–50, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Ozen, N. Ruperto, M. J. Dillon et al., “EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides,” Annals of the Rheumatic Diseases, vol. 65, no. 7, pp. 936–941, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Eleftheriou, T. Cox, D. Saunders, N. J. Klein, P. A. Brogan, and V. Ganesan, “Investigation of childhood central nervous system vasculitis: magnetic resonance angiography versus catheter cerebral angiography,” Developmental Medicine and Child Neurology, vol. 52, no. 9, pp. 863–867, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Wahezi, W. A. Gomes, and N. T. Ilowite, “Cranial nerve involvement with juvenile polyarteritis nodosa: clinical manifestations and treatment,” Pediatrics, vol. 126, no. 3, pp. e719–e722, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Khellaf, M. Hamidou, C. Pagnoux et al., “Vasculitis restricted to the lower limbs: a clinical and histopathological study,” Annals of the Rheumatic Diseases, vol. 66, no. 4, pp. 554–556, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. J. Dillon, D. Eleftheriou, and P. A. Brogan, “Medium-size-vessel vasculitis,” Pediatric Nephrology, vol. 25, no. 9, pp. 1641–1652, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Hashimoto, T. Yano, T. Kawanishi, H. Tsuda, and T. Nagasawa, “Outcome of collagen vascular diseases by treatment with plasmapheresis,” Therapeutic Apheresis, vol. 2, no. 4, pp. 268–272, 1998. View at Scopus
  8. L. Guillevin, R. Cevallos, B. Durand-Gasselin, F. Lhote, B. Jarrousse, and P. Callard, “Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome: indications of plasma exchanges meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis,” Annales de Medecine Interne, vol. 148, no. 3, pp. 198–204, 1997. View at Scopus
  9. S. Ozen, “The spectrum of vasculitis in children,” Best Practice Research in Clinical Rheumatology, vol. 16, no. 3, pp. 411–425, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Gedalia, H. Correa, M. Kaiser, and R. Sorensen, “Steroid sparing effect of intravenous gamma globulin in a child with necrotizing vasculitis,” American Journal of the Medical Sciences, vol. 309, no. 4, pp. 226–228, 1995. View at Scopus
  11. D. Eleftheriou, M. Melo, S. D. Marks et al., “Biologic therapy in primary systemic vasculitis of the young,” Rheumatology, vol. 48, no. 8, pp. 978–986, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Gianviti, R. S. Trompeter, T. M. Barratt, M. F. Lythgoe, and M. J. Dillon, “Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis,” Archives of Disease in Childhood, vol. 75, no. 3, pp. 186–190, 1996. View at Scopus
  13. H.-C. Kuo, K. D. Yang, W.-C. Chang, L.-P. Ger, and K.-S. Hsieh, “Kawasaki disease: an update on diagnosis and treatment,” Pediatrics and Neonatology, vol. 53, no. 1, pp. 4–11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Galeotti, J. Bayry, I. Kone-Paut, and S. V. Kaveri, “Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin,” Autoimmunity Reviews, vol. 9, no. 6, pp. 441–448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Uehara and E. D. Belay, “Epidemiology of Kawasaki disease in Asia, Europe, and the United States,” Journal of Epidemiology, vol. 22, no. 2, pp. 79–85, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. J. W. Newburger, M. Takahashi, M. A. Gerber et al., “Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association,” Pediatrics, vol. 114, no. 6, pp. 1708–1733, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Kato, T. Sugimura, T. Akagi et al., “Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients,” Circulation, vol. 94, no. 6, pp. 1379–1385, 1996. View at Scopus
  18. B. Tabarki, A. Mahdhaoui, H. Selmi, M. Yacoub, and A. S. Essoussi, “Kawasaki disease with predominant central nervous system involvement,” Pediatric Neurology, vol. 25, no. 3, pp. 239–241, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. N. R. Alves, C. M. R. Magalhães, R. D. F. Almeida, et al., “Prospective study of kawasaki disease complications: review of 115 cases,” Revista da Associacao Medica Brasileira, vol. 57, no. 3, pp. 295–300, 2011. View at Scopus
  20. B. García Norniella, M. Morán Poladura, M. Fernández Díaz, E. Fernández Fernández, and C. Suárez Castañón, “Aseptic meningitis secondary to intravenous immunoglobulin treatment in Kawasaki disease,” Anales de Pediatria, vol. 75, no. 1, pp. 79–80, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Takagi, T. Umezawa, T. Saji, K. Morooka, and N. Matsuo, “Meningoencephalitis in Kawasaki disease,” Brain and Development, vol. 22, no. 5, pp. 429–435, 1990. View at Scopus
  22. T. Ichiyama, M. Nishikawa, T. Hayashi, M. Koga, N. Tashiro, and S. Furukawa, “Cerebral hypoperfusion during acute Kawasaki disease,” Stroke, vol. 29, no. 7, pp. 1320–1321, 1998. View at Scopus
  23. M. Mori, T. Imagawa, R. Hara et al., “Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series,” Journal of Rheumatology, vol. 39, no. 4, pp. 864–867, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. W. Newburger, M. Takahashi, A. S. Beiser et al., “A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome,” New England Journal of Medicine, vol. 324, no. 23, pp. 1633–1639, 1991. View at Scopus
  25. K.-P. Weng, S.-F. Ou, C.-C. Lin, and K.-S. Hsieh, “Recent advances in the treatment of Kawasaki disease,” Journal of the Chinese Medical Association, vol. 74, no. 11, pp. 481–484, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. H. Baumer, S. J. Love, A. Gupta, L. C. Haines, I. Maconochie, and J. S. Dua, “Salicylate for the treatment of Kawasaki disease in children,” Cochrane Database of Systematic Reviews, vol. 18, no. 4, article CD004175, 2006. View at Scopus
  27. S. S. Gidding and S. T. Shulman, “Diagnosis and management of children with Kawasaki disease,” Heart Disease and Stroke, vol. 3, no. 4, pp. 210–215, 1994. View at Scopus
  28. T. Imaizumi, Y. Kawasaki, H. Matsuura et al., “Efficacy of steroid pulse, plasmapheresis, and mizoribine in a patient with focal segmental glomerulosclerosis,” Pediatric Nephrology, vol. 22, no. 8, pp. 1215–1218, 2007. View at Scopus
  29. L. L. Blaisdell, J. A. Hayman, and A. M. Moran, “Infliximab treatment for pediatric refractory Kawasaki disease,” Pediatric Cardiology, vol. 32, no. 7, pp. 1023–1027, 2011. View at Scopus
  30. A. H. Rowley and S. T. Shulman, “Recent advances in the understanding and management of kawasaki disease,” Current Infectious Disease Reports, vol. 12, no. 2, pp. 96–102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Suzuki, M. Terai, H. Hamada et al., “Cyclosporin a treatment for kawasaki disease refractory to initial and additional intravenous immunoglobulin,” The Pediatric Infectious Disease Journal, vol. 30, no. 10, pp. 871–876, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. M. J. O'Connor and F. T. Saulsbury, “Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab,” Clinical Pediatrics, vol. 46, no. 4, pp. 345–348, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Oishi, M. Fujieda, T. Shiraishi et al., “Infliximab treatment for refractory kawasaki disease with coronary artery aneurysm—A 1-month-old girl,” Circulation Journal, vol. 72, no. 5, pp. 850–852, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. E. Weiss, B. A. Eberhard, D. Chowdhury, and B. S. Gottlieb, “Infliximab as a novel therapy for refractory Kawasaki disease,” Journal of Rheumatology, vol. 31, no. 4, pp. 808–810, 2004. View at Scopus
  35. F. Zulian, G. Zanon, G. Martini, G. Mescoli, and O. Milanesi, “Efficacy of infliximab in long-lasting refractory Kawasaki disease,” Clinical and Experimental Rheumatology, vol. 24, no. 4, p. 453, 2006. View at Scopus
  36. K. Suda, Y. Kudo, Y. Sugawara, M. Ishii, and T. Matsuishi, “Prevention of thrombosis of coronary aneurysms in patients with a history of Kawasaki disease,” Japanese Journal of Clinical Medicine, vol. 66, no. 2, pp. 355–359, 2008. View at Scopus
  37. N. F. Choueiter, A. K. Olson, D. D. Shen, and M. A. Portman, “Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease,” Journal of Pediatrics, vol. 157, no. 6, pp. 960–966, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. S. M. Huang, K. P. Weng, J. S. Chang, W. Y. Lee, S. H. Huang, and K. S. Hsieh, “Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease—a pilot study,” Circulation Journal, vol. 72, no. 10, pp. 1583–1587, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. J. M. M. Gardner-Medwin, P. Dolezalova, C. Cummins, and T. R. Southwood, “Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins,” The Lancet, vol. 360, no. 9341, pp. 1197–1202, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Vogler, S. C. Eliason, and E. G. Wood, “Glomerular membranopathy in children with IgA nephropathy and Henoch Schonlein purpura,” Pediatric and Developmental Pathology, vol. 2, no. 3, pp. 227–235, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Pillebout, D. Nochy, and E. Thervet, “Henoch-Shönlein purpura,” Nephrologie et Therapeutique, vol. 5, no. 7, pp. 663–675, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Ozen, A. Pistorio, S. M. Iusan et al., “EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria,” Annals of the Rheumatic Diseases, vol. 69, no. 5, pp. 798–806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. C. L. Chen, Y. H. Chiou, C. Y. Wu, P. H. Lai, and H. M. Chung, “Cerebral vasculitis in Henoch-Schonlein purpura: a case report with sequential magnetic resonance imaging changes and treated with plasmapheresis alone,” Pediatric Nephrology, vol. 15, no. 3-4, pp. 276–278, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. A. L. Belman, C. R. Leicher, S. L. Moshe, and A. P. Mezey, “Neurologic manifestations of Schoenlein-Henoch purpura: report of three cases and review of the literature,” Pediatrics, vol. 75, no. 4, pp. 687–692, 1985. View at Scopus
  45. L. Garzoni, F. Vanoni, M. Rizzi et al., “Nervous system dysfunction in Henoch-Schönlein syndrome: systematic review of the literature,” Rheumatology, vol. 48, no. 12, pp. 1524–1529, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. H. L. Zhang and J. Wu, “Posterior reversible encephalopathy syndrome associated with Henoch-Schönlein Purpura,” Pediatric Emergency Care, vol. 26, no. 12, p. 966, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Sasayama, Y. Shimojima, T. Gono, K. Kaneko, M. Matsuda, and S. I. Ikeda, “Henoch-Schönlein purpura nephritis complicated by reversible posterior leukoencephalopathy syndrome,” Clinical Rheumatology, vol. 26, no. 10, pp. 1761–1763, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Hinchey, C. Chaves, B. Appignani et al., “A reversible posterior leukoencephalopathy syndrome,” New England Journal of Medicine, vol. 334, no. 8, pp. 494–500, 1996. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Dasarathi, D. Birchall, C. De San Lazaro, L. K. Fawcett, and J. A. Eyre, “Henoch-Schönlein purpura with posterior reversible encephalopathy syndrome,” Pediatric Neurology, vol. 46, no. 1, pp. 42–43, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Kawasaki, “The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis,” Clinical and Experimental Nephrology, vol. 15, no. 5, pp. 648–657, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Mollica, S. Li Volti, R. Garozzo, and G. Russo, “Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura,” European Journal of Pediatrics, vol. 151, no. 2, pp. 140–144, 1992. View at Scopus
  52. J. Ronkainen, O. Koskimies, M. Ala-Houhala et al., “Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial,” Journal of Pediatrics, vol. 149, no. 2, pp. 241–247, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Oki, K. Tsugawa, K. Suzuki, E. Ito, and H. Tanaka, “Leukocytapheresis for the treatment of refractory Henoch-Schönlein purpura resistant to both prednisolone and intravenous immunoglobulin therapy,” Rheumatology International, vol. 28, no. 8, pp. 823–824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Mendes, M. Correia, M. Barbedo et al., “Behçet's disease—a contemporary review,” Journal of Autoimmunity, vol. 32, no. 3-4, pp. 178–188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. A. B. Robinson, W. B. Gallentine, and C. E. Rabinovich, “Pediatric neuro-Behçet's disease responsive to adalimumab,” Pediatric Neurology, vol. 43, no. 4, pp. 291–293, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Atkinson, E. Moore, D. Altinok, and G. Acsadi, “Cerebral infarct in pediatric Neuro-Behçet's disease,” Journal of Child Neurology, vol. 23, no. 11, pp. 1331–1335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Mitra and R. L. Koul, “Paediatric neuro-Behcet's disease presenting with optic nerve head swelling,” British Journal of Ophthalmology, vol. 83, no. 9, p. 1096, 1999. View at Scopus
  58. A. B. Haghighi and A. Safari, “Proposing an algorithm for treatment of different manifestations of neuro-Behcet's disease,” Clinical Rheumatology, vol. 29, no. 6, pp. 683–686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Hatemi, A. Silman, D. Bang et al., “EULAR recommendations for the management of Behçet disease,” Annals of the Rheumatic Diseases, vol. 67, no. 12, pp. 1656–1662, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. J. C. Nichols, A. Ince, L. Akduman, and E. S. Mann, “Interferon-alpha 2a treatment of neuro-Behcet disease,” Journal of Neuro-Ophthalmology, vol. 21, no. 2, pp. 109–111, 2001. View at Scopus
  61. K. Fujikowa, K. Aratake, A. Kawakami et al., “Successful treatment of refractory neuro-Behçet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile,” Annals of the Rheumatic Diseases, vol. 66, no. 1, pp. 136–137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. J. E. Alty, T. M. Monaghan, and J. M. Bamford, “A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFα blockade,” Clinical Neurology and Neurosurgery, vol. 109, no. 3, pp. 279–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Ribi, R. Sztajzel, J. Delavelle, and C. Chizzolini, “Efficacy of TNF α blockade in cyclophosphamide resistant neuro-Behçet disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 12, pp. 1733–1735, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Sarwar, H. McGrath Jr., and L. R. Espinoza, “Successful treatment of long-standing neuro-Behçet's disease with infliximab,” Journal of Rheumatology, vol. 32, no. 1, pp. 181–183, 2005. View at Scopus
  65. H. Kikuchi, K. Aramaki, and S. Hirohata, “Effect of infliximab in progressive Neuro-Behçet's syndrome,” Journal of the Neurological Sciences, vol. 272, no. 1-2, pp. 99–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Cantarini, I. Tinazzi, P. Caramaschi, F. Bellisai, A. Brogna, and M. Galeazzi, “Safety and efficacy of etanercept in children with juvenile-onset Behcet's disease,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 2, pp. 551–555, 2009. View at Scopus
  67. A. Borhani Haghighi and A. Safari, “Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease,” Medical Hypotheses, vol. 71, no. 1, pp. 156–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Berlit, “Diagnosis and treatment of cerebral vasculitis,” Therapeutic Advances in Neurological Disorders, vol. 3, no. 1, pp. 29–42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Elbers, W. Halliday, C. Hawkins, C. Hutchinson, and S. M. Benseler, “Brain biopsy in children with primary small-vessel central nervous system vasculitis,” Annals of Neurology, vol. 68, no. 5, pp. 602–610, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Ozen, J. Anton, N. Arisoy et al., “Juvenile polyarteritis: results of a multicenter survey of 110 children,” Journal of Pediatrics, vol. 145, no. 4, pp. 517–522, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. L. H. Calabrese, A. J. Furlan, L. A. Gragg, and T. J. Ropos, “Primary angiitis of the central nervous system: diagnostic criteria and clinical approach,” Cleveland Clinic Journal of Medicine, vol. 59, no. 3, pp. 293–306, 1992. View at Scopus
  72. R. A. Hajj-Ali, A. Furlan, A. Abou-Chebel, and L. H. Calabrese, “Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup,” Arthritis Care and Research, vol. 47, no. 6, pp. 662–669, 2002. View at Scopus
  73. R. A. Hajj-Ali and L. H. Calabrese, “Central nervous system vasculitis,” Current Opinion in Rheumatology, vol. 21, no. 1, pp. 10–18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. L. H. Calabrese, D. W. Dodick, T. J. Schwedt, and A. B. Singhal, “Narrative review: reversible cerebral vasoconstriction syndromes,” Annals of Internal Medicine, vol. 146, no. 1, pp. 34–44, 2007. View at Scopus
  75. E. S. Sen, V. Leone, M. Abinun et al., “Treatment of primary angiitis of the central nervous system in childhood with mycophenolate mofetil,” Rheumatology, vol. 49, no. 4, pp. 806–811, 2010. View at Scopus
  76. C. Hutchinson, J. Elbers, W. Halliday et al., “Treatment of small vessel primary CNS vasculitis in children: an open-label cohort study,” The Lancet Neurology, vol. 9, no. 11, pp. 1078–1084, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. M. A. Alba, G. Espígol-Frigolé, S. Prieto-González et al., “Central nervous system vasculitis: still more questions than answers,” Current Neuropharmacology, vol. 9, no. 3, pp. 437–448, 2011. View at Publisher · View at Google Scholar · View at Scopus